GlassScriptPhysician profile
Nicholas Tarangelo
NPI 1073909925
$5,362.93
in general payments reported to CMS, 2019-2025
27 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $457 · 2023: $1,121 · 2024: $1,836 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,906.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,661.90 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $844.40 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $417.89 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $344.72 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $271.76 | 2023-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $222.99 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $216.48 | 2023-2025 | Stelara, Tremfya, Simponi |
| Intercept Pharmaceuticals, INC. | $196.55 | 2022-2025 | Ocaliva |
| Pfizer INC. | $180.24 | 2024-2025 | |
| Ardelyx, INC. | $159.08 | 2023-2025 | Ibsrela |
| Celgene Corporation | $112.03 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $102.98 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $91.68 | 2023-2025 | Rebyota, Clenpiq |
| Nestle Healthcare Nutrition INC. | $81.58 | 2023 | |
| Braintree Laboratories, INC. | $80.89 | 2023-2025 | Sutab, Suflave |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $74.38 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $66.90 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $36.81 | 2025 | Vegzelma |
| Genzyme Corporation | $36.76 | 2024 | |
| Vivus LLC | $35.59 | 2025 | Qsymia |
| Blueprint Medicines Corporation | $23.51 | 2025 | Ayvakit |
| Medtronic, INC. | $20.92 | 2024 | Endoflip |
| Sanofi Pasteur INC. | $18.05 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.00 | 2025 | Voquezna |
| Orphalan INC | $16.26 | 2024 | Cuvrior |
| Organon LLC | $15.45 | 2024 | |
| Merck Sharp & Dohme LLC | $15.13 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Tarangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.